1. Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial. Issue 9 (September 2022) Authors: Turkova, Anna; Waalewijn, Hylke; Chan, Man K; Bollen, Pauline D J; Bwakura-Dangarembizi, Mutsa F; Kekitiinwa, Adeodata R; Cotton, Mark F; Lugemwa, Abbas; Variava, Ebrahim; Ahimbisibwe, Grace Miriam; Srirompotong, Ussanee; Mumbiro, Vivian; Amuge, Pauline; Zuidewind, Peter; Ali, Shabinah; Kityo, Ci... Journal: Lancet Issue: Volume 9:Issue 9(2022) Page Start: e627 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial. Issue 5 (May 2018) Authors: Mallewa, Jane; Szubert, Alexander J; Mugyenyi, Peter; Chidziva, Ennie; Thomason, Margaret J; Chepkorir, Priscilla; Abongomera, George; Baleeta, Keith; Etyang, Anthony; Warambwa, Colin; Melly, Betty; Mudzingwa, Shepherd; Kelly, Christine; Agutu, Clara; Wilkes, Helen; Nkomani, Sanele; Musiime, Vict... Journal: Lancet Issue: Volume 5:Issue 5(2018) Page Start: e231 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. Issue 6 (June 2022) Authors: Paton, Nicholas I; Musaazi, Joseph; Kityo, Cissy; Walimbwa, Stephen; Hoppe, Anne; Balyegisawa, Apolo; Asienzo, Jesca; Kaimal, Arvind; Mirembe, Grace; Lugemwa, Abbas; Ategeka, Gilbert; Borok, Margaret; Mugerwa, Henry; Siika, Abraham; Odongpiny, Eva Laker A; Castelnuovo, Barbara; Kiragga, Agnes; Ka... Journal: Lancet Issue: Volume 9:Issue 6(2022) Page Start: e381 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial. (4th March 2018) Authors: Siika, Abraham; McCabe, Leanne; Bwakura-Dangarembizi, Mutsa; Kityo, Cissy; Mallewa, Jane; Berkley, Jay; Maitland, Kath; Griffiths, Anna; Baleeta, Keith; Mudzingwa, Shepherd; Abach, James; Nathoo, Kusum; Thomason, Margaret J; Prendergast, Andrew J; Walker, Ann Sarah; Gibb, Diana M Journal: Clinical infectious diseases Issue: Volume 66(2018)Supplement 2 Page Start: S140 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. Issue 9 (September 2022) Authors: Amuge, Pauline; Lugemwa, Abbas; Wynne, Ben; Mujuru, Hilda A; Violari, Avy; Kityo, Cissy M; Archary, Moherndran; Variava, Ebrahim; White, Ellen; Turner, Rebecca M; Shakeshaft, Clare; Ali, Shabinah; Nathoo, Kusum J; Atwine, Lorna; Liberty, Afaaf; Bbuye, Dickson; Kaudha, Elizabeth; Mngqibisa, Rosie;... Journal: Lancet Issue: Volume 9:Issue 9(2022) Page Start: e638 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗